Dr. Bob Sheeler’s webinar will highlight three tools replacing trial and error with biology-driven treatments.

IntellxxDNA screens hundreds of DNA variants across brain health, detoxification, and metabolic function to guide broad, personalized care plans.

GeneSight analyzes genes tied to drug metabolism and neurotransmitter function to predict which psychiatric medications are likely to work, need adjustment, or cause side effects, sparing patients repeated medication trials.

Phenomix, through its MyPhenome test, classifies patients into obesity phenotypes to predict GLP-1 response before treatment starts. For likely nonresponders, phenotype-matched alternatives like phentermine/topiramate or naltrexone/bupropion offer an effective, often lower-cost path forward